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Abstract 24	
Antibiotics are used for fighting pathogens, but also target our commensal bacteria as a side 25	
effect, disturbing the gut microbiota composition and causing dysbiosis and disease1-3. 26	
Despite this well-known collateral damage, the activity spectrum of the different antibiotic 27	
classes on gut bacteria remains poorly characterized. Having monitored the activities of 28	
>1,000 marketed drugs on 38 representative species of the healthy human gut microbiome4, 29	
we here characterize further the 144 antibiotics therein, representing all major classes. We 30	
determined >800 Minimal Inhibitory Concentrations (MICs) and extended the antibiotic 31	
profiling to 10 additional species to validate these results and link to available data on 32	
antibiotic breakpoints for gut microbes. Antibiotic classes exhibited distinct inhibition spectra, 33	
including generation-dependent effects by quinolones and phylogeny-independence by β-34	
lactams. Macrolides and tetracyclines, two prototypic classes of bacteriostatic protein 35	
synthesis inhibitors, inhibited almost all commensals tested. We established that both kill 36	
different subsets of prevalent commensal bacteria, and cause cell lysis in specific cases. 37	
This species-specific activity challenges the long-standing divide of antibiotics into 38	
bactericidal and bacteriostatic, and provides a possible explanation for the strong impact of 39	
macrolides on the gut microbiota composition in animals5-8 and humans9-11. To mitigate the 40	
collateral damage of macrolides and tetracyclines on gut commensals, we exploited the fact 41	
that drug combinations have species-specific outcomes in bacteria12 and sought marketed 42	
drugs, which could antagonize the activity of these antibiotics in abundant gut commensal 43	
species. By screening >1,000 drugs, we identified several such antidotes capable of 44	
protecting gut species from these antibiotics without compromising their activity against 45	
relevant pathogens. Altogether, this study broadens our understanding of antibiotic action on 46	
gut commensals, uncovers a previously unappreciated and broad bactericidal effect of 47	
prototypical bacteriostatic antibiotics on gut bacteria, and opens avenues for preventing the 48	
collateral damage caused by antibiotics on human gut commensals.   49	
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MAIN TEXT 50	
Medication is emerging as major contributor for changes in the composition of the human gut 51	
microbiota4,13-15. Such severe and long-lasting changes are associated, and in some cases 52	
causatively linked, to dysbiosis and a wide range of diseases16. Although several non-53	
antibiotic drugs may also have a previously unappreciated impact on the gut microbiome 54	
composition4,16,17, antibiotics, developed to have broad spectra and thereby target very 55	
diverse pathogens, are long known to take a heavy toll on our gut flora, causing a variety of 56	
gastrointestinal side-effects18, including Clostridioides (former Clostridium) difficile infections. 57	
Recently more attention has been given to this collateral damage of antibiotics on the gut 58	
microbiota and thereby on the host’s wellbeing. In vivo studies highlight links between the 59	
long-term microbiota compositional changes and host dysbiosis, including the development 60	
of allergic, metabolic, immunological and inflammatory diseases5-8,10,11,19-21. While uncovering 61	
the direct effects of different antibiotics on our gut flora is critical to improve general health, 62	
technical difficulties hamper routine testing of antibiotic susceptibility in anaerobes22,23. 63	
Currently available data on bacterial susceptibility to antibiotics is focused on invasive 64	
pathogens and offers little to no resolution in the diversity of the human gut microbiota24. 65	
Information is missing even for the most prevalent and abundant gut species, or ones 66	
recently associated with dysbiosis and disease25,26. In addition, existing animal or cohort 67	
studies have used a handful of antibiotics or merge data from different antibiotic classes, 68	
precluding systematic and general conclusions on the matter.  69	
We recently assessed the direct effect of ~1200 FDA-approved drugs on the growth 70	
of 38 prevalent and abundant or disease-associated human gut species under anaerobic 71	
conditions at a fixed concentration of 20 µM4. This initial screen (referred to hereafter as 72	
“screen”) included 144 antibiotics (Fig. 1a, Extended Data Fig. 1, Suppl. Table 1), with 73	
different classes having discernible effects on gut microbes (Fig. 1b). We validated these 74	
results by measuring 815 MICs (33 antibiotics and 2 antifungals for 17 species, 22 antibiotics 75	
for 10 additional species), using MIC gradient test strips (Fig. 1a, Extended Data Fig. 2, 76	
Suppl. Table 2 + 3). Despite differences in the experimental procedure, concordance 77	
.CC-BY 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.09.893560doi: bioRxiv preprint 
	 4	
between data from the initial screen and MICs is very high: Specificity and sensitivity of 0.97 78	
(Extended Data Fig. 3a). The newly established MICs also correlate well with available data 79	
on antimicrobial susceptibility from databases such as EUCAST24 or ChEMBL27 (rs=0.69 and 80	
rs=0.64, respectively), despite differences in strains and media used (Extended Data Fig. 3b). 81	
Importantly, this new dataset considerably expands the available MICs, as much as by 80% 82	
for non-pathogenic bacteria (Fig. 1c, Extended Data Fig. 3c). Altogether, the initial screen 83	
and the new MIC dataset provide high-resolution information on the target spectrum of 84	
antibiotics on commensal gut microbes, which we explored further.  85	
The antibiotics tested exhibited strong class-dependent effects (Fig. 1b, d). 86	
Consistent with literature, aminoglycosides hardly affected gut microbes under anaerobic 87	
conditions28 and sulfonamides were inactive in the medium used for the screen4. Quinolones 88	
acted in a generation-dependent manner. First-generation variants were effective only on a 89	
narrow spectrum of microbes that included both commensal E. coli tested. Second- and 90	
third- generation quinolones increased the spectrum. Fourth-generation variants (developed 91	
to increase activity against anaerobes) inhibited all tested species, except for Akkermansia 92	
muciniphila (Fig. 1e, Extended Data Fig. 1, red box), a species associated with protection 93	
against different diseases and dysbiotic states29, and even positive responses to 94	
immunotherapy30. For β-lactams, resistance was patchy but distinct for different members 95	
and subclasses (Extended Data Fig. 2, 4a). For Bacteroidetes, we tested additional species 96	
and strains (in total 12 and 19, respectively) (Extended Data Fig. 4b, c), confirming that β-97	
lactam sensitivity and phylogenetic relatedness are uncoupled (Extended Data Fig. 4d). This 98	
argues for resistance mechanisms being strain-specific and horizontally transferred. 99	
Macrolides showed a strong impact on gut commensals and inhibited all tested microbes 100	
(Fig. 1d), except for the opportunistic pathogen C. difficile, which was resistant to all tested 101	
macrolides and clindamycin (Extended data Fig. 2, red box). This is in line with the 102	
associated risk of C. difficile infection after macrolide/clindamycin treatment31. Finally, 8 of 103	
the 9 tested tetracyclines inhibited nearly all tested microbes, which is surprising in the light 104	
of the gut microbiota being considered as reservoir for tetracycline resistance genes32.  105	
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Concentration-resolved MICs confirmed the same drug class-dependent trends observed in 106	
the screen (Fig. 1d, f). In addition, MICs allow for comparisons with clinical breakpoints, i.e. 107	
MICs at which a species should be considered resistant or susceptible (Fig. 1f). Overall, the 108	
gut microbes in our assays (anaerobic growth, gut mimetic growth medium33) were slightly 109	
more resistant to most antibiotic classes than previously reported for pathogens (aerobic 110	
growth, Mueller-Hinton agar). Tetracyclines were the exception, inhibiting commensals at 111	
significantly lower concentrations than what is reported for pathogens (Fig. 1f). Thus, 112	
commensals might be considerably less resistant to tetracyclines than previously anticipated 113	
and suggested by the detection of tetracycline resistance elements in fecal metagenomes.  114	
Recent in-vivo studies have shown that β-lactams and macrolides have a strong and 115	
long-lasting collateral impact on the gut microbiota composition and thereby on host health5-8. 116	
As β-lactams exhibited strain-specific effects (Extended Data Fig. 1, 2, 4) and are known to 117	
kill bacteria (bactericidal), they could irrevocably deplete specific members of the gut 118	
microbiota, thereby explaining their differential and long-lasting effects on the community 119	
composition. On the other hand, macrolides uniformly targeted all tested gut commensals 120	
(Fig. 1d) and are textbook bacteriostatic antibiotics, i.e. inhibit bacterial growth, but do not kill 121	
(at least at high numbers). In this case, the long-term community composition change is 122	
more difficult to rationalize, as all community members are inhibited, but should be able to 123	
regrow once drug is removed. Similarly, tetracyclines, another class of bacteriostatic 124	
antibiotics that acted on nearly all gut microbes we tested, have known gastro-intestinal side-125	
effects18, which are indicative of gut microbiome dysbiosis. We thus wondered at which level 126	
macrolides and tetracyclines exert a differential effect on gut microbes. Although traditionally 127	
both clinical use34-37 and basic research38,39 heavily rely on this distinction between 128	
bactericidal and bacteriostatic antibiotics, there are reports of drugs changing their killing 129	
capacity depending on the organism, drug concentration or medium tested40,41 (and 130	
increased evidence from meta-analyses that the distinction may have little relevance to 131	
clinical practice42,43). We therefore hypothesized that this bacteriostatic/bactericidal divide 132	
may be less rigid for gut commensals, which are more phylogenetically diverse than the few 133	
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pathogens usually tested, and hence provide a level where the effect of these drug classes 134	
on gut microbes becomes differential.  135	
The standard way to determine whether an antibiotic has bactericidal or bacteriostatic 136	
activity is to calculate time-kill curves, where the bacterial survivors are counted on agar at 137	
various time-points after drug treatment. If, over a significant period of antibiotic treatment 138	
(ranging from 5 to 24 hours), the number of colony forming units (CFU)/ml of culture 139	
decreases by more than 99.9%, the antibiotic is considered bactericidal40. We assessed the 140	
survival of 12 abundant gut microbes over a 5-hour treatment of either a macrolide 141	
(erythromycin or azithromycin) or a tetracycline (doxycycline) at 5 x MIC (Fig 2a + b, 142	
Extended Data Fig. 5). About half of the tested species decreased in survival by >99.9%, 143	
pointing to these drugs being bactericidal to several abundant gut microbes. To confirm this 144	
further, we tested the viability of B. vulgatus and E. coli ED1a upon erythromycin, 145	
azithromycin or doxycycline treatments using live/dead staining. Microscopy and flow 146	
cytometry assessment of live/dead bacteria corroborated the initial observations (Fig. 2c, 147	
Extended Data Fig. 6). As tetracyclines are considered bona-fide bacteriostatic drugs in E. 148	
coli, we were surprised to see that doxycycline effectively killed the commensal E. coli ED1a 149	
(Fig. 2a). We verified that these effects held also in the presence of oxygen (Extended Data 150	
Fig. 7a) and confirmed that doxycycline has a stronger bactericidal action on this natural 151	
isolate than on the domesticated E. coli K-12 lab strain, BW25113 (Extended Data Fig. 7b). 152	
In parallel, we excluded that the differences in killing capacity were confounded by growth 153	
rate, growth phase or MIC of the bacterial species tested (Extended Data Fig. 8). We also 154	
noticed that B. vulgatus and B. uniformis cultures decreased density in the presence of 155	
erythromycin (Fig. 2d). We confirmed by time-lapse microscopy that this was due to lysis. 156	
Erythromycin caused cell shape defects, including blebbing, cytoplasmic shrinkage, and 157	
ultimately cell lysis in both B. vulgatus and B. uniformis (Figure 2e, Movies 1-4). Altogether, 158	
this selective bactericidal activity of macrolides and tetracyclines on specific gut commensals 159	
could provide an explanation for the strong effects these drug classes have on the gut 160	
microbiota composition of human individuals. The gut microbes killed from the drug would be 161	
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inadvertently removed from community, whereas the ones being only inhibited could recover 162	
when the therapy stops.   163	
Knowing that drug combinations often have species-specific outcomes12, we 164	
reasoned that we could identify drugs that selectively antagonize the effect of antibiotics on 165	
gut microbes, while retaining activity against pathogens. Therefore, we screened the 166	
Prestwick library to identify antagonizing compounds to erythromycin or doxycycline on two 167	
abundant and prevalent gut microbes, B. vulgatus and B. uniformis (Fig. 3a, Extended Data 168	
Fig. 9). Of the 19 identified hits (Fig. 3b, Suppl. Table 4), we tested the 14 candidates with 169	
the strongest activity in a concentration-dependent manner (Extended Data Fig. 10a). Nine 170	
retained antagonistic activity over a broader concentration range, which we confirmed by 171	
checkerboard assays (Fig. 3c). The antidotes that showed the strongest antagonisms were 172	
the anticoagulant drug dicumarol, and two non-steroidal anti-inflammatory drugs, tolfenamic 173	
acid and diflunisal. While dicumarol rescued B. vulgatus from erythromycin and diflunisal 174	
from doxycycline, tolfenamic acid was able to protect B. vulgatus from both drugs. In 175	
addition, these interactions were able to at least partially rescue the killing of B. vulgatus by 176	
erythromycin and doxycycline (Extended Data Fig. 10b). We then probed two of these drugs 177	
for their ability to protect other abundant gut commensals and confirmed that both dicumarol 178	
and tolfenamic acid were able to counteract erythromycin on several species (Fig. 3d, 179	
Extended Data Fig. 11). In contrast, both drugs did not affect the potency of erythromycin on 180	
Staphylococcus aureus, Streptococcus pneumoniae and Enterococcus faecium, pathogens 181	
against which erythromycin is active/prescribed (Fig. 3e, Extended Data Fig. 12a). For 182	
example, tolfenamic acid and dicumarol at concentration ranges of 5-40 µM could rescue the 183	
growth of five out of seven tested abundant gut commensal species at clinically relevant 184	
erythromycin concentrations (Fig. 3f, Extended Data Fig. 12b). Altogether, our data provides 185	
a proof-of-principle for identifying antidotes that specifically mask the collateral damage of 186	
antibiotics on commensals. This concept would need to be further validated in the future in 187	
animal models. Antidotes may also need to be modified to late (colon)-release or non-188	
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absorbable formulations to ensure they reach the gut and to minimize adverse effects from 189	
their primary action. 190	
In summary, our study provides a high-resolution map of the collateral damage of 191	
antibiotics on 50 different resident gut microbes down to the level of individual drugs, species 192	
and partially even strains. We challenge the universal divide of antibiotics into bacteriostatic 193	
and bactericidal across bacteria, as this breaks down when tested beyond model organisms. 194	
Antibiotics with preferential killing of some species may be the most detrimental to our gut 195	
flora, although the first studies in a few healthy individuals point to the gut microbiota having 196	
some resilience against specific antibiotic regimens44. Understanding the underlying 197	
mechanisms for this selective killing might open up ways for the development of new 198	
antimicrobials, but also strategies for controlled microbiome modulation15. Finally, we provide 199	
a proof-of-concept that species-specificity of drug combinations12 can be exploited to identify 200	
antidotes that selectively protect the gut microbiota from the adverse effects of systemic 201	
antibiotic therapy. This new approach adds to proposed and existing strategies of gut 202	
microbiota protection against antibiotics, such as co-administration of activated charcoal45, β-203	
lactamases46, probiotics or (autologous) fecal transplants47. Overall, our results suggest that 204	
interactions of antibiotics and commensals merit deeper exploration, as our current 205	
knowledge of the mode(s) of action of antibiotics in model pathogens is not necessarily 206	
transferable to commensals.  207	
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METHODS 208	
Growth conditions 209	
All experiments from this study were performed in an anaerobic chamber (Coy Laboratory 210	
Products Inc) (2% H2, 12% CO2, 86% N2) and all materials and solutions used for these 211	
experiments were pre-reduced for at least 24 h before use unless specified otherwise. 212	
Bacteria used in this study were typically pre-cultured for two overnights: Cells were cultured 213	
in 5 ml modified Gifu Anaerobic Medium broth (MGAM) (HyServe GmbH & Co.KG, Germany, 214	
produced by Nissui Pharmaceuticals) and grown at 37°C overnight. The next day, cells were 215	
diluted 1/100 in 5 ml MGAM medium and grown at 37°C for a second overnight before 216	
starting the experiments.  217	
 218	
Quantitative assay for minimum inhibitory concentration determination with MICs test 219	
strips 220	
MICs test strips were purchased from Liofilchem or Oxoid (Suppl. Table 2). All MICs were 221	
measured under anaerobic growth conditions inside a Coy anaerobic chamber. Bacteria 222	
were precultured in MGAM for two overnights and cultures were diluted to OD578 = 0.5. 50 µl 223	
of the diluted culture were spread on a MGAM agar plate and allowed to dry for 15 min. The 224	
MIC test strip was placed on the agar with sterile tweezers, allowing the part with the lowest 225	
concentration touch the agar first. Plates were incubated at 37°C inside the anaerobic 226	
chamber, at least overnight and longer depending on the species-specific growth 227	
requirements. After formation of a symmetrical inhibition ellipse, plates were taken out of the 228	
chamber and imaged under controlled lighting conditions (spImager S&P Robotics Inc.) using 229	
an 18 megapixel Canon Rebel T3i (Canon Inc. USA). MICs were directly determined from 230	
the strip scale at the point where the edge of the inhibition ellipse intersects the MIC test 231	
strip. All MICs were determined in duplicates. In cases of an eight-fold difference between 232	
the two values, a third replicate was done. In all cases, this resulted in a clear outlier (> 8-fold 233	
different from other two MICs) that was removed from the dataset.  234	
 235	
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MIC comparison to ChEMBL and EUCAST databases 236	
Previously known MICs were extracted from the ChEMBL database (version 24)27 and 237	
EUCAST (obtained on May 14, 2018)24. Antibiotics from these two datasets were mapped to 238	
our dataset by name. Species were mapped using NCBI Taxonomy Identifiers and species 239	
names. For MICs from ChEMBL, a keyword-based approach was used to exclude 240	
experiments on species with mutations, deletions, insertions, etc. The EUCAST database 241	
contains a large number of reported MICs for each compound–species pair. We collapsed 242	
these to a single value by calculating the median MIC.  243	
Estimates on the abundance and prevalence of species in the healthy human gut 244	
microbiome were calculated using mOTUs v248 as follows: Relative species abundances 245	
were determined in 727 shotgun metagenomic samples from donors in the control groups of 246	
multiple studies from various countries and continents49-53. Prior to taxonomic profiling, 247	
metagenomes were quality controlled using the MOCAT2 -rtf procedure54, which removed 248	
reads with ≥95% sequence identity and an alignment length of ≥45bp to the human genome 249	
hg19. Taxonomic profiles were then created using mOTUs version 2.1.048 with parameters -l 250	
75 ; -g 2; and -c. Afterwards relative abundances below 10-4 were set to zero and species 251	
with nonzero abundance in <5 samples discarded. For the retained 1,350 species, 252	
prevalence was defined as the percentage of samples with nonzero abundance; a 253	
prevalence cut-off of 1% was chosen to classify species into “rare” and “common” species. 254	
For all species in the MIC dataset, we manually assessed their status as pathogenic or non-255	
pathogenic species using encyclopaedic and literature knowledge. Pathogenic species that 256	
occur in more than 1% of healthy people (i.e. are designated as “common”) were classified 257	
as “potentially pathogenic species” that can, for example, cause diseases in 258	
immunocompromised patients.  259	
 260	
Killing curves and survival assay 261	
Cells were precultured as described in the growth conditions section before being diluted to 262	
an OD578=0.01 and grown for 2 h at 37°C (unless specified otherwise). Next, cells were 263	
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diluted 1/2 in MGAM containing a 10-fold MIC of erythromycin, azithromycin or doxycycline 264	
(final antibiotic concentration is 5-fold MIC) and incubated in the presence of the antibiotic for 265	
5 h at 37°C. At several time-points (0, 1h, 2h, 3h, 4h, 5h), 100 µl of cells were serial-diluted in 266	
PBS (10-1 to 10-8 dilutions) and plated on MGAM-Agar plates for CFU counting. When no 267	
cells were detected using this method, a bigger volume of culture (up to 2 ml) was plated to 268	
be able to detect CFUs. Agar plates were incubated overnight at 37°C and colonies were 269	
counted the next day, either manually, for low CFU numbers, or using the Analyze Particles 270	
tool from ImageJ55.  271	
 272	
Live/dead staining 273	
Cells were precultured as described in the growth conditions section before being diluted to 274	
an OD578=0.01 and grown for 2 h at 37°C. Cells were next diluted 1/2 in MGAM containing 275	
10-fold MIC of erythromycin, azithromycin or doxycycline (final concentration is 5-fold the 276	
MIC) and incubated in the presence of the antibiotic for 5 h at 37°C. Then, cells were 277	
live/dead stained using the LIVE/DEAD BacLight Bacterial viability and counting kit (#L34856 278	
Molecular Probes, ThermoFisher) according to the manufacturer's protocol before and after 279	
antibiotic treatment.  280	
 281	
Flow cytometry 282	
Stained cells were counted using a BD LSRFortessaTM flow cytometer. The forward and side 283	
scatter signals (488 nm) as well as the green and red fluorescent signals (488-530/30A filter 284	
and 561-610/20A filter, respectively) were acquired. The FSC/SSC detectors were set to 285	
logarithmic scale. The flow rate varied between 12 µl/min and 60 µl/min depending on the 286	
concentration of each sample, and the analysis was stopped when 10,000 target events 287	
were measured. Graphs were generated using the FlowJo V10.3 software (Treestar). 288	
 289	
Microscopy 290	
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For live/dead imaging, stained cells were washed twice in 0.85% NaCl before being spotted 291	
on 0.85% NaCl +1% agarose pads between a glass slide and a coverslip. For time-lapse 292	
imaging, cells were precultured as described in the growth conditions section. Cells were 293	
then diluted to an OD578=0.01 and grown for 3 h at 37°C before being spotted on MGAM 294	
+1% agarose pads, supplemented or not with 15 µg/ml erythromycin (5-fold MIC) between a 295	
glass slide and a coverslip. Slides were sealed with valap (to avoid/delay oxygen 296	
permeation) and taken outside of the anaerobic chamber for imaging. In these conditions, 297	
untreated bacteria kept growing rapidly (Movie 1 + 3). The imaging was performed using a 298	
Nikon Eclipse Ti inverted microscope, equipped with a Nikon DS-Qi2 camera, a Nikon Plan 299	
Apo Lambda 60X oil Ph3 DM phase contrast objective and a Nikon HC mCherry filter set (Ex 300	
562/40; DM 593; BA 641/75) to detect propidium iodide fluorescence. Images were acquired 301	
with the NIS-Elements AR4.50.00 software and processed with Fiji v.2.0.0-rc-68/1.52h56.  302	
 303	
Growth curves 304	
Cells were precultured as described in the growth conditions section. Then, cells were diluted 305	
to an OD578=0.01 in a 96-well plate sealed with a breathable membrane (Breathe-Easy®) 306	
and grown for 2 h. Next, erythromycin was added to the culture to a final concentration of 15 307	
µg/ml (5-fold MIC) and growth curves were acquired for 20 h using a microplate 308	
spectrophotometer (EON, Biotek) by measuring the OD578 every hour after 30 sec of linear 309	
shaking.  310	
 311	
Screen for microbiome-protective antibiotic antagonism 312	
Preparation of screening plates. The Prestwick Chemical Library was purchased from 313	
Prestwick Chemical Inc. and drugs were re-arrayed, diluted and stored in 96 well format as 314	
described before4. We prepared drug plates (2 x drug concentration) in MGAM medium and 315	
stored them at -30°C. For each experiment, drug plates were thawed, supplemented with the 316	
respective antibiotic solution (freshly prepared in MGAM) and pre-reduced in the anaerobic 317	
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chamber overnight. All rearranging and aliquoting steps were done using the Biomek FXP 318	
(Beckman Coulter) system.  319	
Inoculation and screening conditions. Strains were grown twice overnight, the second 320	
overnight culture was diluted in MGAM to reach OD578 nm 0.04 (4 x the desired starting OD). 321	
25 µl of the diluted cultures were used to inoculate wells containing 50 µl of 2x concentrated 322	
Prestwick drug and 25 µl of the 4x concentrated antibiotic using the semi-automated, 96-well 323	
multi-channel pipette epMotion96 (Eppendorf). Each well contained 1% DMSO, 20 µM of the 324	
Prestwick drug and a species-specific antibiotic concentration that was just inhibitory for the 325	
respective strain (0.625 µM for erythromycin, 0.04 µM doxycycline for B. uniformis and 0.08 326	
µM doxycycline for B. vulgatus). Plates were sealed with breathable membranes (Breathe-327	
Easy®) and OD578 was measured hourly after 30 sec of linear shaking with a microplate 328	
spectrophotometer (EON, Biotek) and an automated microplate stacker (Biostack 4, Biotek) 329	
fitted inside a custom-made incubator (EMBL Mechanical Workshop). Growth curves were 330	
collected up to 24 h. For each antibiotic, each species was screen in biological duplicates. All 331	
experiments included control wells of unperturbed growth (32 wells per run) and control wells 332	
for growth in the presence of the antibiotic only (8 wells per plate).  333	
Analysis pipeline and hit calling. All growth curves within a plate were truncated at the 334	
transition time from exponential to stationary phase and converted to normalized AUCs using 335	
in-run control wells (no drug) as described before4 .We then calculated z-scores based on 336	
these normalized AUCs, removed replicates with 8-fold differences in z-scores to eliminate 337	
noise effects, computed mean z- scores across the two replicates and selected combinations 338	
with mean z-scores > 3. This selection included 19 potential antibiotic antagonists and we 339	
followed up on 14 of them (7 potential erythromycin and 7 potential doxycycline antagonists 340	
in either B. vulgatus or B. uniformis – see Extended Data Fig. 9) in independent experiments.  341	
Validation of microbiome-protective antagonists. First, we kept the erythromycin/doxycycline 342	
concentration constant (0.625 µM for erythromycin, 0.078 µM (B. vulgatus)/ 0.039 µM (B. 343	
uniformis) for doxycycline) and tested concentration gradients of the potential antagonists 344	
with ranges depending on the antagonist’s solubility. Compounds were purchased from 345	
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independent vendors (Suppl. Table 5) and dissolved at 100x starting concentration in DMSO. 346	
Eight 2-fold serial dilutions were prepared in 96-well plates with each row containing a 347	
different antagonist, sufficient control DMSO wells and wells with just the respective antibiotic 348	
(‘antibiotic-only’ control). These master plates were diluted in MGAM medium (50 µl) to 2 x 349	
assay concentration and 25 µl freshly prepared antibiotic solution (4x test concentration) was 350	
added. Plates were pre-reduced overnight in an anaerobic chamber and inoculated with 25 351	
µl of overnight cultures (prepared as described under Growth conditions) to reach a starting 352	
OD578 of 0.01 and 1% DMSO concentration. Growth was monitored hourly for 24 h after 30 353	
sec of linear shaking (as described for the screen4). Experiments were performed in 354	
biological triplicates. For analysis, growth curves were converted into normalized AUCs (see 355	
above). We accounted for residual growth in the presence of the antibiotic by subtracting the 356	
median normalized AUCs of the ‘antibiotic-only’ control per plate. We computed medians 357	
across triplicates and considered a normalized AUC > 0.25 as concentration-dependent 358	
growth rescue by the antagonist.  359	
Checkerboard assays for anaerobic commensals. Validated antagonists were further 360	
investigated in 8x8 checkerboard assays, where both antibiotics and antagonists were 361	
titrated against each other. Such assays were first performed for the commensals that were 362	
originally screened (i. e. B. vulgatus and B. uniformis – 4 replicates) and later expanded 363	
towards six further gut microbes (B. caccae, B. fragilis NT, B. ovatus, B. thetaiotaomicron, P. 364	
copri, P. distasonis – 2 replicates). For vertical gradients, 2-fold serial dilutions of the 365	
antagonists were prepared first in 100x in DMSO and diluted in MGAM as described above 366	
(section ‘Validation of microbiome-protective antagonists’). Horizontal antibiotic dilution 367	
series were freshly prepared in MGAM at 4x final concentration in equidistant concentration 368	
steps. Both, vertical and horizontal dilution series were combined (50 µl of the antagonist 369	
gradients (2x) and 25 µl of the antibiotic gradients (4x)) in 96 well plates. Plates were pre-370	
reduced under anaerobic conditions overnight, inoculated with 25 µl of diluted overnight 371	
culture (at 4x starting OD) and sealed with breathable membrane (Breathe-Easy®). Bacterial 372	
growth was monitored once per hour for 24 h after 30 sec linear shaking (Eon + Biostack 4, 373	
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Biotek) under anaerobic conditions. Growth curves were converted into normalized AUCs as 374	
described using in-plate controls to define unperturbed growth.  375	
Checkerboard assays for pathogens under aerobic conditions. For three pathogens (S. 376	
aureus DSM20231 ATCC 12600 and E. faecium ATCC19434) 8x8 checkerboard assays 377	
were performed in transparent 384 well plates (Greiner BioOne GmbH), with each well 378	
containing a total volume of 30 µl in total for S. aureus and 55 µl for E. faecium. S. aureus 379	
strains were grown in tryptic soy broth (TSB, Sigma Aldrich), E. faecium in BHI medium 380	
(Sigma Aldrich). Drugs were arrayed in 2-fold serial dilutions for the checkerboards. Cell 381	
were inoculated at initial OD595nm ~0.01 from an overnight culture. Plates were sealed with 382	
breathable membranes (Breathe-Easy), incubated at 37°C (Cytomat 2, Thermo Scientific) 383	
with continuous shaking and OD595nm was measured every 30 min for 16 h in a Filtermax F5 384	
multimode plate reader (Molecular Devices).  For S. pneumoniae D39, we only tested 385	
concentration gradients of the potential antagonists in a constant antibiotic concentration (0.2 386	
µM erythromycin) in BHI medium. All experiments were done at least in 2 biological 387	
replicates and 2 technical replicates. Wells in which there was significant condensation were 388	
removed and background due to medium was subtracted. Growth curves were trimmed at 389	
the transition to stationary phase (9 h for S. aureus, 12 h for E. faecium). AUCs were 390	
calculated and normalised by the median of the internal no-drug control wells (n = 6). 391	
Interactions were quantified according to the Bliss interaction model57. Interactions were 392	
called antagonistic if the median of all the interaction scores for a given checkerboard was 393	
above 0.05, synergistic if the value was below -0.05 and neutral if lying between these two 394	
cut-offs.  395	
 396	
Phylogenetic analysis/phylogenetic tree construction 397	
In order to generate a phylogenetic tree for the different isolates, the nucleotide sequences 398	
for a set of universally occurring, protein coding, single copy phylogenetic marker genes48,58 399	
were extracted from reference genomes or genome assemblies using fetchMG58 400	
(https://motu-tool.org/fetchMG.html). Within the framework of the ete3 toolkit59, 401	
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ClustalOmega60 was used to create sequence alignments for each marker gene 402	
independently and all columns with more than 10% gaps were removed. The individual 403	
alignments were concatenated and finally, a phylogenetic tree was inferred from the 404	
combined alignment using IQTree61. 405	
 406	
Data availability 407	
Data is available upon request.  408	
 409	
Code availability 410	
Code is available upon request. 411	
 412	
  413	
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 Figure 1 –Activity spectrum of antibiotic classes on human gut commensals.  
a. Overview of antibiotics tested in initial screen at 20 µM concentration4 and validated by MIC determination in this study. b. Principal 
component analysis based on AUCs from the initial screen on the effects of antibiotics on gut commensals. Antibiotic classes drive some 
separation at the phylum level, e.g. beta-lactams separate Bacteroidetes and macrolides/lincosamides/streptogramins separate Proteobacteria. 
c. Comparison of MICs from this study to MICs available from public databases. Species are classified as “common” or “rare” if they are present 
in the gut microbiome of more or less than 1% of 727 healthy individuals, respectively (see Methods). d. For the main antibiotic classes from the 
screen, the numbers of inhibited strains are shown (N as in a). 40 strains tested in total at a 20 µM antibiotic concentration. Boxes span the IQR 
and whiskers extend to the most extreme data points up to a max of 1.5 times the IQR. e. Number of inhibited strains per (fluoro-)quinolone drug 
generation. Number of tested drugs per generation is indicated in brackets on x-axis labeling. Boxplots as in panel d. f. MICs of drug-species 
pairs for the main antibiotic classes measured in this study are depicted next to EUCAST clinical (susceptibility) breakpoints for pathogens. 
Numbers of drug-species pairs (MICs; colored) and of antibiotic per class (EUCAST clinical breakpoints; grey) are shown in brackets. Boxplots 
as in panel, d, y-axis is log2 scale. 
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Figure 2 - Macrolides and tetracyclines kill human gut commensal species 
a. The survival of 12 abundant gut microbe species was measured after a 5-hour treatment with a 5-fold MIC of erythromycin (ERY), 
azithromycin (AZI) or doxycycline (DOX). The survival was assessed by counting CFUs/ml before and after antibiotic treatment. The number of 
CFUs/ml before treatment was set as 100%. The detection limit for each experiment (gray bar) and the bactericidal threshold (shaded area) are 
indicated. Species are plotted according to phylogeny (IQTree, Methods) and in bold are noted the species that are used in later panels. The 
graph shows the mean+SD of 3 independent experiments. b. Time-kill curves of B. vulgatus, R. intestinalis and F. nucleatum after antibiotic 
treatments. Survival was assessed by CFU counting over a 5 hour-treatment of ERY, AZI or DOX. This graph shows the mean±SD of 3 
independent experiments. Nd: non-detectable. Time-kill curves for the other tested gut microbes can be found in Extended Data Fig. 5. c.  
Live/dead staining of macrolide or tetracycline-treated B. vulgatus. The left panel shows an overlay of phase contrast and fluorescence 
microscopy images of propidium iodide (PI)-stained B. vulgatus before and 5 hours after ERY, AZI or DOX treatment. Cultures were 
concentrated before imaging; the scale bar is 10 µm. The right panel shows the corresponding quantification of live/dead-stained cells by flow 
cytometry with Syto9 on the x-axis (live cells) and PI on the y-axis (dead cells). Both the total number of measured events (n) and the 
percentage of cells found in each quadrant are indicated. d. Erythromycin induces lysis of B. vulgatus and B. uniformis. B. vulgatus and B. 
uniformis were grown for 3 hours before addition (yellow) or not (black) of 15 µg/ml ERY treatment (5-fold MIC; yellow) as indicated by the 
arrow. Growth curves were acquired for 20 hours. This graph shows the mean±SD (dotted line) of 3 independent experiments. e. Erythromycin 
induces blebbing, cytoplasmic shrinkage and lysis in B. vulgatus and B. uniformis. Phase contrast movies of B. vulgatus and B. uniformis were 
acquired after ERY treatment (5-fold MIC). Here shown 3 frames of 3 images per strain (time indicated in the upper left corner; t=0 when drug 
added). White arrows indicate blebs, cytoplasmic shrinkage and bacterial lysis; the scale bar is 5 µm. Movies are available in Supplementary 
Material (Movies 1-4). 
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Figure 3 – Antidotes for selective protection of prevalent and abundant gut commensal species from macrolides and tetracyclines. 
a. Schematic illustration of the screen concept: searching for antidote compounds that antagonize the antibacterial effect of erythromycin or 
doxycycline on commensal but not on pathogenic bacteria. b. Z-scores on bacterial growth (based on areas under the curve (AUCs)) for 
combinatorial drug exposure with antibiotic (ERY or DOX) and FDA-approved drug. Compounds that successfully rescued B. vulgatus and/or B. 
uniformis growth in the presence of the antibiotic (z-score > 3) are indicated in gray. The strongest hits (circles) were validated further in 
concentration-dependent assays (Extended Data Fig. 10a). For each antibiotic and each strain, ~1200 drugs were tested in two replicates. 
Boxplots are defined as in Figure 1d. c. For 9 of the validated antagonists, 8 x 8 checkerboard assays were performed to determine 
concentration ranges of the antagonistic interaction. Heat maps depict bacterial growth based on normalized median of AUCs of 4 replicates. All 
interactions were antagonistic, and pairs tested further in other commensal species are framed in bold. d. Checkerboard assays confirm the 
ability of tolfenamic acid to protect further gut commensals from growth inhibition by erythromycin. Heat map as in c, but for 2 replicates. 
Antagonistic interactions are framed in red. e. Checkerboard of tolfenamic acid with erythromycin reveal neutral interactions in S. aureus and E. 
faecium (aerobic conditions). Heat maps as in c, based on at least two independent experiments with two technical replicates each. f. 
Tolfenamic acid concentration-dependent rescue of commensal growth at clinical relevant erythromycin concentrations based on AUCs 
(anaerobic conditions). Erythromycin still retains its activity against pertinent pathogens such as S. aureus, E. faecium and S. pneumoniae 
(aerobic conditions). 0.625 µM correspond to ~0.5 µg/ml erythromycin, which is in the range of the MIC breakpoints for Staphylococcus (1 
µg/ml), S. pneumoniae (0.25 µg/ml) and Streptococci groups A, B, C & G (0.25 µg/ml). Error bars depict standard deviation. 
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Extended Data Figure 1 – Effects of 144 antibiotics on 40 human gut commensals 
Heat map according to sensitivity or resistance of each strain to the respective antibiotic at a concentration of 20 µM. Antibiotics are grouped 
according to drug classes and species are clustered according to their responses across the 144 antibiotics tested. Data is replotted from4. 
Akkermansia muciniphila (Muc, DSM22959, type strain) is resistant to nearly all quinolone antibiotics (red box). We consolidated this finding by 
MIC determination for Ciprofloxacin (>32 µg/ml), Gatifloxacin (>32 µg/ml), Moxifloxacin (>32 µg/ml), Norfloxacin (>256 µg/ml) and Ofloxacin 
(>32 µg/ml).  
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Extended Data Figure 2 – MICs for 17 species on 35 antimicrobials 
Heat map depicts MICs for each drug-strain pair in µg/ml. Heat map color gradient is adjusted to the MICs concentration range tested on the 
respective MIC test strip. Black depicts sensitivity and light grey indicates resistance. Mean values across two biological replicates are shown 
(Suppl. Table 3). C. difficile is particularly resistant to all tested macrolides and clindamycin (red box).  
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Extended Data Figure 3 – MIC dataset validates antibiotic sensitivity profiles from the screen dataset and is consistent with publically 
available MICs.  
a. Receiver operating characteristic (ROC) curve analysis was performed to evaluate sensitivity and specificity of the screen4 using the MIC 
dataset. Results from the screen were considered as validated if MICs were below/above the 20 µM antibiotic concentration that was tested in 
the screen (allowing a two-fold error margin). N is the number of antibiotics that we tested both in the screen and determined MICs for, AUROC 
is the area under the characteristic ROC. TN denotes true negatives, FP false positives, TP true positives, FN false negatives.  
b. Comparison including Spearman correlation coefficients of the MICs from this study to MICs from the ChEMBL 27 and EUCAST 24 databases. 
Panels in the upper row: comparison between all MICs that are shared between the two indicated datasets. Panels in the lower row: comparison 
of the 69 MICs that are shared across all three datasets. Despite experimental differences, our MICs correlate well with available EUCAST/ 
ChEMBL data.  
c. Number of the sum of new (this study) and already available MICs (EUCAST/ ChEMBL) per drug according to antibiotic class and 
prevalence/virulence of the bacterial species. The new dataset expands MICs across the board and specifically fills the knowledge gap on non-
pathogenic species. 
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Extended Data Figure 4 – β-lactam antibiotic resistance profiles do not recapitulate phylogenetic relationship between Bacteroides 
spp.  
a. Number of inhibited Bacteroides spp. (out of 8 tested) at 20 µM per β-lactam subclass, based on the initial screen4. Number of drugs per class 
tested are shown in parenthesis. Boxes plotted as in Figure 1d.   
b.  Overview of the number of drugs tested per β-lactam subclasses on Bacteroides spp.; compared to ED Figure 2, 10 additional strains were 
tested: B. eggerthii, B. clarus, B. coprocola, B. vulgatus HM-720, B. xylanisolvens, B. fragilis HM-709, B. fragilis HM-710, B. uniformis HM-716, 
B. dorei and B. stercoris. 
c. MIC heat map for 8 β-lactam antibiotics on 19 Bacteroides spp. Strains are clustered according to resistance profiles across all β-lactam 
antibiotics, drugs are clustered according their effects on Bacteroides spp. MICs values are based on two biological replicates and are partially 
replotted from Extended Data Fig. 2. Heat map gradients are adjusted to the antibiotic concentration ranges tested with lighter color depicting 
resistance and darker color depicting sensitivity.  
d. Heat map of phylogenetic relationship between Bacteroides spp (upper triangular matrix) ordered by phylogeny and their resistance profiles 
across β-lactam antibiotics (lower triangular matrix). Colors represent the pairwise phylogenetic distance and the Euclidean distance on the log2 
transformed MICs for β-lactams (panel c). Examples of strains from the same species (B. fragilis / B. uniformis) that respond differently to β-
lactam antibiotics, are highlighted.  
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Extended Data Figure 5 - Time-kill curves of 12 abundant gut microbes after treatment with macrolides and tetracyclines.  
Survival of 12 abundant gut microbes was assessed by CFU counting over a 5 hour-treatment of either ERY, AZI or DOX. This graph shows the 
mean±SD of 3 independent experiments. 
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Extended Data Figure 6 - Live/dead staining of macrolide or tetracycline-treated E. coli ED1a.  
The left panel shows an overlay of phase contrast and fluorescence microscopy images of propidium iodide (PI)-stained E. coli ED1a before and 
5 hours after ERY, AZI or DOX treatments. The number of cells on each frame has no meaning, as cultures were concentrated before imaging; 
the scale bar is 10 µM. The right panel shows the corresponding quantification of live/dead-stained cells by flow cytometry with Syto9 on the x-
axis (live cells) and PI on the y-axis (dead cells). Both the total number of measured events (n) and the percentage of cells found in each 
quadrant are indicated on the graphs. 
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Extended Data Figure 7 - Effect of oxygen and strain specificity on survival after doxycycline treatment 
a. The survival of E. coli ED1a was assessed after a 5-hour treatment with 5-fold MIC of DOX in the presence or absence of oxygen. Killing was 
similarly effective in both conditions. 
b. The survival of E. coli ED1a and E. coli BW25113 were assessed after a 5-hour treatment with 1, 2 and 5-fold MIC of DOX in MGAM medium 
in anaerobic conditions. The lab strain is more resistant to killing with doxycycline becoming boarder-line bactericidal at higher MICs. 
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Extended Data Figure 8 – Assessing potential confounding factors for the killing capacities of erythromycin, azithromycin and 
doxycycline   
a. Scatter plot of individual bacterial growth rates and percentage survival after a 5-hour treatment with 5-fold MIC of ERY, AZI or DOX 
treatments. r indicates the Spearman correlation coefficient. Tested species are color-coded here and in all panel thereafter as indicated in the 
bottom of this figure. Positive correlations for macrolides were tested further in b to check if changing growth rate in same species affects 
percentage killed. 
b. The survival of B. fragilis (blue) and F. nucleatum (beige) were assessed after a 5-hour macrolide treatment (5-fold MIC of ERY and AZI) at 
either 30°C (slow growth) or 37°C (fast growth) to test the effect of slowing down growth on survival. No significant change observed. This graph 
shows the mean±SD of three independent experiments.  
c. Scatter plot of MICs and percentage survival after a 5-hour treatment with 5-fold MIC of ERY, AZI or DOX treatments. r indicates the 
Spearman correlation coefficient. Doxycycline exhibited a strong and significant anti-correlation, that is that species which were more sensitive 
to doxycycline (lower MIC) were not killed when they were treated with 5-fold MIC concentrations. Thus, we tested further whether increasing 
the drug concentration in some of those sensitive strains decreased the % of survival (panel d). 
d. The survival of B. fragilis (blue) and F. nucleatum (beige) were assessed after a 5-hour treatment with increasing concentrations of DOX (5, 
10 or 20- fold of MIC) to test whether higher concentrations of DOX induced more killing. This seemed not be the case. This graph shows the 
mean±SD of three independent experiments.  
e. To evaluate whether outgrowth of stationary phase and homogeneity of population affected our results, we selected two slow-growing strains, 
E. rectale and R. intestinalis and grew for 2 or 3 hours after being diluted from an overnight culture to an of OD578 0.01. Both strains were then 
treated for 5 hours with 5-fold MIC of ERY, AZI or DOX and their survival was assessed to test the impact of the growth phase on the 
percentage survival. Although slight differences were observed and 3h grown cultures were killed more effectively (presumably because more 
cells had exited stationary phase and were growing exponentially by then), the general trends remained the same. If anything, this means that 
we are underestimating the killing for slow-growers, since we performed all other experiments with 2 hours outgrowth. This graph shows the 
mean±SD of three independent experiments.  
f. The survival of 8 selected gut microbes was measured after treating cells in exponential phase (E – 2 hours after dilution from an overnight 
culture) or in stationary phase (S – overnight growth) with 5-fold MIC of ERY for 5 hours to test the impact of the growth phase on the 
percentage survival. As expected, survival is higher in stationary phase for half of the strains, but in some cases stationary phase cells were as 
or more sensitive than exponentially growing cells – this is the case for B. caccae and F. nucleatum. This graph shows the mean±SD of three 
independent experiments. 
g. Same as in f but with DOX. Similar effects observed as in f, with more than half of strains becoming more resistant in stationary phase. 
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Extended Data Figure 9 – Schematic overview of screen for microbiome-protective antibiotic antagonisms 
Workflow with decision process on which antagonist to move on to next evaluation step. 
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Extended Data Figure 10 – Validation of potential microbiome-protective antagonists 
a. Validation of the strongest antagonists in independent experiments. Erythromycin and doxycycline concentrations were kept constant 
([ERY]=0.625 µM, [DOX] = 0.039 / 0.078 µM) and concentration ranges were tested for antagonist. Asterisks indicate that at least 25% of the 
bacterial growth (compared to no drug controls) could be rescued by the antagonist at a given concentration. Heat map depicts median AUCs 
across triplicates.  
b. Percentage of surviving B. vulgatus cells were determined after 5 h incubation with either erythromycin (3.25µM) or doxycycline (0.4 µM) 
alone or in presence of the antagonist dicumarol (20 µM), tolfenamic acid (40 µM) or diflunisal (80 µM). Data is based on 3 independent 
experiments. Boxplots are plotted as in Figure 1d.  
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Extended Data Figure 11 – Effect of antidotes on further gut commensals 
8 x 8 checkerboard assays to investigate if antidote is also protective for additional gut commensals for the following combinations: erythromycin 
and dicumarol (a), doxycycline and diflunisal (b) and doxycycline and tolfenamic acid (c). Heat map depicts bacterial growth based on median 
AUCs from two independent replicates. Red contours indicate antagonistic drug interactions.  
 
.CC-BY 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.09.893560doi: bioRxiv preprint 
 36 
 
 
 
Extended Data Figure 12– Effect of the antidote dicumarol on pathogens, relatively to commensal species. 
a. Checkerboard assays for the drug combinations erythromycin-tolfenamic acid and erythromycin-dicumarol on the pathogens S. aureus (two 
different strains) and E. faecium. Heat map depict median normalized AUCs of checkerboard assays (at least three independent replicates).  
b. Dicumarol rescues commensal growth (based on median AUCs, N=2) at clinical relevant erythromycin concentrations in a concentration-
dependent manner. Erythromycin still retains its activity against pertinent pathogens such as S. aureus, E. faecium and S. pneumoniae and is 
even slightly more active (synergy) for E. faecium (based on median AUCs, N=3). Error bars depict standard deviation. 
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